
Conference Coverage
Latest Content

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%

How Portable Oxygen Is Changing Home Respiratory Care: Doug Francis

Health Equity & Access Weekly Roundup: July 24, 2026

Polygenic Risk Scores Move Closer to IPF Clinical Use: David Zhang, MD

FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis

Shorts










Podcasts
Center on Health Equity & Access
All News

June 2026 brought 5 FDA firsts across infectious disease, oncology, and rare disease, expanding treatment options and addressing unmet patient needs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Clesrovimab remained well tolerated through a second RSV season in infants at increased risk of severe RSV.

The Pharmacy Compounding Advisory Committee meets July 23-24 to discuss whether pharmacies may dispense BPC-157, TB-500, and 5 other peptides.

Dermatologists spend 13 hours weekly on prior authorization as health plans tout an 11% reduction in requests.

Use of automated insulin delivery technology improves a Healthcare Effectiveness Data and Information Set quality measure in individuals with type 2 diabetes.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

New York City health officials confirmed a 5th fatality in the Upper East Side Legionnaires' disease outbreak.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.





















